Ethinylestradiol/norethisterone acetate

Last updated

Ethinylestradiol/norethisterone acetate
Combination of
Ethinylestradiol Estrogen
Norethisterone acetate Progestogen
Clinical data
Trade names Femlyv, Estrostep, Loestrin, Microgestin, others [1]
Other namesEE/NETA
AHFS/Drugs.com Professional Drug Facts
License data
Routes of
administration 		By mouth
ATC code
Legal status
Legal status
Identifiers
CAS Number
PubChem CID
KEGG
Chemical and physical data
3D model (JSmol)
  • CC(=O)OC1(CCC2C1(CCC3C2CCC4=CC(=O)CCC34)C)C#C.CC12CCC3C(C1CCC2(C#C)O)CCC4=C3C=CC(=C4)O
  • InChI=1S/C22H28O3.C20H24O2/c1-4-22(25-14(2)23)12-10-20-19-7-5-15-13-16(24)6-8-17(15)18(19)9-11-21(20,22)3;1-3-20(22)11-9-18-17-6-4-13-12-14(21)5-7-15(13)16(17)8-10-19(18,20)2/h1,13,17-20H,5-12H2,2-3H3;1,5,7,12,16-18,21-22H,4,6,8-11H2,2H3/t17-,18+,19+,20-,21-,22-;16-,17-,18+,19+,20+/m01/s1
  • Key:GEONECATAKDDLT-JDSZYESASA-N

Ethinylestradiol/norethisterone acetate (EE/NETA), or ethinylestradiol/norethindrone acetate, is a combination of ethinylestradiol (EE) and norethisterone acetate (NETA) which is used as birth control and menopausal hormone therapy. [1] [3] EE is an estrogen, while norethisterone acetate (NETA) is a progestin. [1] It is taken by mouth. [1] Some preparations of EE/NETA used in birth control additionally contain an iron supplement in the form of ferrous fumarate. [4]

Contents

Norethindrone acetate and ethinyl estradiol have been approved in the US for the prevention of pregnancy as a swallowable tablet since 1968. [5] In 2022, the combination of ethinylestradiol with norethisterone or with norethisterone acetate was the 80th most commonly prescribed medication in the United States, with more than 8 million prescriptions. [6] [7] It is available as a generic medication. [8]

Medical uses

Ethinylestradiol/norethisterone acetate is indicated for use by females of reproductive potential to prevent pregnancy. [9]

Ethinylestradiol/norethisterone acetate is also indicated in women with an intact uterus for the treatment of moderate to severe vasomotor symptoms associated with the menopause; and for prevention of postmenopausal osteoporosis. [3] [10] [11]

Society and culture

In July 2024, the US Food and Drug Administration (FDA) approved Femlyv, the first orally disintegrating tablet for the prevention of pregnancy. [5] Norethindrone acetate and ethinyl estradiol have been approved in the US for the prevention of pregnancy as a swallowable tablet since 1968. [5]

Brand names

Brand names include Anovlar, Blisovi, Cumorit, Estrostep, Femhrt, Femlyv, Fyavolv, Gildess, Junel, [12] Larin, Leribane, Loestrin, Lo Loestrin (Lo Lo), Mibelas, Microgestin, Minastrin, Norlestrin, Primodos, Taytulla, and Tri-Legest, among others. [8] [13]

See also

References

  1. 1 2 3 4 "Estrogen-Progestin Combinations Monograph for Professionals". Drugs.com. AHFS. Retrieved 28 December 2018.
  2. ↑ "Lolo Product information". Health Canada . 6 May 2024. Retrieved 17 February 2025.
  3. 1 2 Rowan JP, Simon JA, Speroff L, Ellman H (June 2006). "Effects of low-dose norethindrone acetate plus ethinyl estradiol (0.5 mg/2.5 microg) in women with postmenopausal symptoms: updated analysis of three randomized, controlled trials". Clin Ther. 28 (6): 921–32. doi:10.1016/j.clinthera.2006.06.013. PMID   16860174.
  4. ↑ Willihnganz M, Clayton AD (1 May 2014). Basic Pharmacology for Nurses - E-Book. Elsevier Health Sciences. pp. 648–. ISBN   978-0-323-29309-9.
  5. 1 2 3 "FDA Roundup: July 23, 2024". U.S. Food and Drug Administration (FDA) (Press release). 23 July 2024. Archived from the original on 24 July 2024. Retrieved 25 July 2024.PD-icon.svg This article incorporates text from this source, which is in the public domain .
  6. ↑ "The Top 300 of 2022". ClinCalc. Archived from the original on 30 August 2024. Retrieved 30 August 2024.
  7. ↑ "Ethinyl Estradiol; Norethindrone Drug Usage Statistics, United States, 2013 - 2022". ClinCalc. Retrieved 30 August 2024.
  8. 1 2 "Competitive Generic Therapy Approvals". U.S. Food and Drug Administration (FDA). 29 June 2023. Archived from the original on 29 June 2023. Retrieved 29 June 2023.
  9. ↑ "Femlyv Full Prescribing Information" (PDF). Food and Drug Administration. Retrieved 17 January 2025.
  10. ↑ "Femhrt- norethindrone acetate/ethinyl estradiol tablet". DailyMed. 14 November 2017. Retrieved 31 December 2019.
  11. ↑ "Drug Approval Package: Femhrt (Norethindrone Acetate & Ethinyl Estradiol) NDA #21065". U.S. Food and Drug Administration (FDA). Retrieved 28 December 2018.
  12. ↑ "Junel 21 Day- norethindrone acetate and ethinyl estradiol tablet; Junel Fe 28 Day- norethindrone acetate and ethinyl estradiol and ferrous fumarate kit". DailyMed. 14 August 2023. Retrieved 27 February 2024.
  13. ↑ "Ethinyl Estradiol and Norethindrone (Professional Patient Advice)". Drugs.com. 13 July 2019. Retrieved 10 April 2020.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.